Skip to main content
Top
Published in: PharmacoEconomics 15/2003

01-10-2003 | Original Research Article

Indirect costs in ambulatory patients with HIV/AIDS in Spain

A pilot study

Authors: Dr Juan Oliva, César Roa, Juan del Llano

Published in: PharmacoEconomics | Issue 15/2003

Login to get access

Abstract

Objective: To estimate indirect costs in Spanish ambulatory patients with HIV/AIDS and to identify changes in employment status and their current QOL.
Method: Information was obtained through 32 interviews/enquiries carried out with ambulatory patients receiving medical attention at Gregorio Marañón and Puerta de Hierro hospitals in Madrid, Spain. The study variables included information on sociodemographics, economics, and clinical and QOL (EuroQol instrument; EQ-5D) parameters of these patients.
Results: Our main result showed the existence of high indirect costs (lost income and lost wages; 2002 values) at the individual level. We identified a strong effect in terms of income loss (the annual loss of income ranged between €5271 and €6150 per patient) and lost wages (the annual loss of wages ranged between €7537 and €8793 per patient). We also observed a strong impact on household income (the annual loss of household income ranged between €6693 and €7813). There was a great variability in these costs among the patients depending on their QOL, gender and education. We detected a statistically significant and positive correlation between QOL and having a job.
Conclusions: We observed a high level of QOL among the patients, which reflects the potential benefits of pharmacological treatment. We found that the better the QOL, the higher the probability of being employed. However, indirect costs were high among patients despite their good QOL.
Literature
1.
go back to reference Fauci AS. The AIDS Epidemic: considerations for the 21st century. N Engl J Med 1999; 341: 1046–50PubMedCrossRef Fauci AS. The AIDS Epidemic: considerations for the 21st century. N Engl J Med 1999; 341: 1046–50PubMedCrossRef
2.
go back to reference Casabona J. Sida o infectión por VIH? Implicaciones sanitarias. Med Clin (Bare) 1999; 112: 335–6 Casabona J. Sida o infectión por VIH? Implicaciones sanitarias. Med Clin (Bare) 1999; 112: 335–6
3.
go back to reference Ojo K, Delaney M. Economic and demographic consequences of AIDS in Namibia: rapid assessment of the costs. Int J Health Plann Manage 1997; 12: 315–26PubMedCrossRef Ojo K, Delaney M. Economic and demographic consequences of AIDS in Namibia: rapid assessment of the costs. Int J Health Plann Manage 1997; 12: 315–26PubMedCrossRef
4.
go back to reference Cabasés Hita JM. Cuánto nos cuesta el Sida? Med Clin (Bare) 1995; 104: 573–5 Cabasés Hita JM. Cuánto nos cuesta el Sida? Med Clin (Bare) 1995; 104: 573–5
5.
go back to reference Beck EJ, Miners AIL, Tolley K. The cost of HIV treatment and care: a global review. Pharmacoeconomics 2001 Jan; 19 (1): 13–39PubMedCrossRef Beck EJ, Miners AIL, Tolley K. The cost of HIV treatment and care: a global review. Pharmacoeconomics 2001 Jan; 19 (1): 13–39PubMedCrossRef
8.
go back to reference Castilla J, De la Fuente L. Evolución del número de personas infectadas por el virus de la inmunodeficiencia humana y de los casos de sida en España: 1980–1998. Med Clin (Bare) 2000; 115: 85–9 Castilla J, De la Fuente L. Evolución del número de personas infectadas por el virus de la inmunodeficiencia humana y de los casos de sida en España: 1980–1998. Med Clin (Bare) 2000; 115: 85–9
9.
go back to reference Encuesta hospitalaria sobre la utilización de recursos y caracteristicas de los pacientes VIH/sida. Madrid: Ministerio de Sanidad y Consumo, 1998 Nov Encuesta hospitalaria sobre la utilización de recursos y caracteristicas de los pacientes VIH/sida. Madrid: Ministerio de Sanidad y Consumo, 1998 Nov
10.
go back to reference Antonanzas VF, Anton F, Juarez C, et al. Cálculos de los costes del sida en España mediante técnicas de simulación. Med Clin (Bare) 1995; 104: 568–72 Antonanzas VF, Anton F, Juarez C, et al. Cálculos de los costes del sida en España mediante técnicas de simulación. Med Clin (Bare) 1995; 104: 568–72
11.
go back to reference Mompo C, Abbas I, Santin M, et al. La utilización de recursos sanitarios en pacientes infectados por el VIH: creation de una base de datos y obtención de resultados de costes. Gac Sanit 2000 Enero/febrero; 14 (1): 39–47PubMed Mompo C, Abbas I, Santin M, et al. La utilización de recursos sanitarios en pacientes infectados por el VIH: creation de una base de datos y obtención de resultados de costes. Gac Sanit 2000 Enero/febrero; 14 (1): 39–47PubMed
12.
go back to reference Pinto JL, Lopez Lavid C, Badia X, et al. Análisis coste efec-tividad del tratamiento antirretroviral de gran actividad en pacientes infectados por el VIII asintomáticos. Med Clin (Bare) 2000; 114 Suppl. 3: 62–7 Pinto JL, Lopez Lavid C, Badia X, et al. Análisis coste efec-tividad del tratamiento antirretroviral de gran actividad en pacientes infectados por el VIII asintomáticos. Med Clin (Bare) 2000; 114 Suppl. 3: 62–7
13.
go back to reference Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999 May 28; 13 (8): 963–9PubMedCrossRef Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999 May 28; 13 (8): 963–9PubMedCrossRef
14.
go back to reference Kahn JG, Marseille E. Fighting global AIDS: the value of cost-effectiveness analysis. AIDS 2000 Nov 10; 14 (16): 2609–10PubMedCrossRef Kahn JG, Marseille E. Fighting global AIDS: the value of cost-effectiveness analysis. AIDS 2000 Nov 10; 14 (16): 2609–10PubMedCrossRef
15.
go back to reference Lapins DL, Urdaneta ME, Barrett J, et al. Costs of care for HIV infection in a managed care population from 1995 to 1997. Am J Manag Care 2000 Sep; 6 (9): 973–81PubMed Lapins DL, Urdaneta ME, Barrett J, et al. Costs of care for HIV infection in a managed care population from 1995 to 1997. Am J Manag Care 2000 Sep; 6 (9): 973–81PubMed
16.
go back to reference Wallace MR, Tasker SA, Shinohara YT, et al. The changing economics of HIV care. AIDS Patient Care STDS 2001 Jan; 15 (1): 25–9PubMedCrossRef Wallace MR, Tasker SA, Shinohara YT, et al. The changing economics of HIV care. AIDS Patient Care STDS 2001 Jan; 15 (1): 25–9PubMedCrossRef
17.
go back to reference Sendi P, Palmer AJ, Gafni A, et al. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics 2001; 19 (7): 709–13PubMedCrossRef Sendi P, Palmer AJ, Gafni A, et al. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics 2001; 19 (7): 709–13PubMedCrossRef
18.
go back to reference Oliva J. La valoración de los costes indirectos en la evaluation sanitaria. Med Clin (Bare) 2000; 114 Suppl. 3: 15–21 Oliva J. La valoración de los costes indirectos en la evaluation sanitaria. Med Clin (Bare) 2000; 114 Suppl. 3: 15–21
19.
go back to reference Mullins CD, Whitelaw G, Cooke JL, et al. Indirect cost of HIV infection in England. Clin Ther 2000 Nov; 22 (11): 1333–45PubMedCrossRef Mullins CD, Whitelaw G, Cooke JL, et al. Indirect cost of HIV infection in England. Clin Ther 2000 Nov; 22 (11): 1333–45PubMedCrossRef
20.
go back to reference Sendi PP, Bücher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. AIDS 1999; 13: 1115–22PubMedCrossRef Sendi PP, Bücher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. AIDS 1999; 13: 1115–22PubMedCrossRef
21.
go back to reference Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344 (11): 824–31PubMedCrossRef Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344 (11): 824–31PubMedCrossRef
22.
go back to reference Johannesson M. The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy 1996; 36: 232–44CrossRef Johannesson M. The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy 1996; 36: 232–44CrossRef
23.
go back to reference Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 1996; 5: 13–23PubMedCrossRef Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 1996; 5: 13–23PubMedCrossRef
24.
go back to reference Pinto JL, Puig-Junoy J. El coste de oportunidad del tiempo remunerado en la production [working paper]. Madrid: Funda-ción BBVA, 2001 Pinto JL, Puig-Junoy J. El coste de oportunidad del tiempo remunerado en la production [working paper]. Madrid: Funda-ción BBVA, 2001
25.
go back to reference Liljas B. How to calculate indirect costs in economic evaluation. Pharmacoeconomics 1998; 13 (1): 1–7PubMedCrossRef Liljas B. How to calculate indirect costs in economic evaluation. Pharmacoeconomics 1998; 13 (1): 1–7PubMedCrossRef
26.
go back to reference Patella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 (13): 853–60CrossRef Patella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 (13): 853–60CrossRef
27.
go back to reference Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344 (11): 824–31PubMedCrossRef Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344 (11): 824–31PubMedCrossRef
28.
go back to reference Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceutical: Canada. 2nd ed. Ottawa (ON): Canadian Office for Health Technology Assessment (COOHTA), 1997 Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceutical: Canada. 2nd ed. Ottawa (ON): Canadian Office for Health Technology Assessment (COOHTA), 1997
29.
go back to reference Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ 1996; 5: 279–96PubMedCrossRef Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ 1996; 5: 279–96PubMedCrossRef
Metadata
Title
Indirect costs in ambulatory patients with HIV/AIDS in Spain
A pilot study
Authors
Dr Juan Oliva
César Roa
Juan del Llano
Publication date
01-10-2003
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 15/2003
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200321150-00005

Other articles of this Issue 15/2003

PharmacoEconomics 15/2003 Go to the issue